NZ333845A - Long-acting Fmoc-substituted and Fm-substituted pro-drugs - Google Patents
Long-acting Fmoc-substituted and Fm-substituted pro-drugsInfo
- Publication number
- NZ333845A NZ333845A NZ333845A NZ33384597A NZ333845A NZ 333845 A NZ333845 A NZ 333845A NZ 333845 A NZ333845 A NZ 333845A NZ 33384597 A NZ33384597 A NZ 33384597A NZ 333845 A NZ333845 A NZ 333845A
- Authority
- NZ
- New Zealand
- Prior art keywords
- fmoc
- prodrugs
- substituted
- carboxyl
- radical
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title abstract 7
- 239000000651 prodrug Substances 0.000 title abstract 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 125000000524 functional group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 2
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- VRKCDEWVVXAWCZ-UHFFFAOYSA-N amino(nitro)sulfamic acid Chemical compound [O-][N+](=O)N(N)S(O)(=O)=O VRKCDEWVVXAWCZ-UHFFFAOYSA-N 0.000 abstract 1
- -1 amino, carboxyl Chemical group 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 108010006025 bovine growth hormone Proteins 0.000 abstract 1
- 229940106164 cephalexin Drugs 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229960002292 piperacillin Drugs 0.000 abstract 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 abstract 1
- 229920000024 polymyxin B Polymers 0.000 abstract 1
- 229960005266 polymyxin b Drugs 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 abstract 1
- 229960003712 propranolol Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11902996A IL119029A0 (en) | 1996-08-07 | 1996-08-07 | Long-acting drugs and pharamaceutical compositions comprising them |
| PCT/IL1997/000265 WO1998005361A2 (en) | 1996-08-07 | 1997-08-05 | Long-acting drugs and pharmaceutical compositions comprising them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ333845A true NZ333845A (en) | 2000-09-29 |
Family
ID=11069166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ333845A NZ333845A (en) | 1996-08-07 | 1997-08-05 | Long-acting Fmoc-substituted and Fm-substituted pro-drugs |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6504005B1 (enExample) |
| EP (1) | EP1019089B1 (enExample) |
| JP (1) | JP4416184B2 (enExample) |
| KR (1) | KR20000029806A (enExample) |
| CN (1) | CN1227501A (enExample) |
| AT (1) | ATE308998T1 (enExample) |
| AU (1) | AU725468B2 (enExample) |
| BR (1) | BR9711045A (enExample) |
| CA (1) | CA2261835C (enExample) |
| CZ (1) | CZ36999A3 (enExample) |
| DE (1) | DE69734607T2 (enExample) |
| DK (1) | DK1019089T3 (enExample) |
| ES (1) | ES2252787T3 (enExample) |
| HU (1) | HUP0000809A2 (enExample) |
| IL (3) | IL119029A0 (enExample) |
| NO (1) | NO990518L (enExample) |
| NZ (1) | NZ333845A (enExample) |
| WO (1) | WO1998005361A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL139400A0 (en) * | 2000-11-01 | 2001-11-25 | Yeda Res & Dev | Long-acting cytokine derivatives and pharmaceutical compositions comprising them |
| EP1390061A2 (en) * | 2000-12-13 | 2004-02-25 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| NZ531460A (en) | 2001-10-19 | 2005-05-27 | Idexx Lab Inc | Controlled release - over at least 4-15 days - of injectable compositions comprising a lipophilic counterion such a saturated or unsaturated C10-C18 fatty acid |
| US6946137B2 (en) * | 2001-10-19 | 2005-09-20 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| BE1015608A6 (fr) * | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
| JP4033382B2 (ja) * | 2002-04-08 | 2008-01-16 | 久光製薬株式会社 | インスリン投与装置 |
| SG153699A1 (en) * | 2003-01-16 | 2009-07-29 | Caprotec Bioanalytics Gmbh | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions |
| CA2843439A1 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd | Reversible pegylated drugs |
| WO2004091601A1 (fr) * | 2003-04-17 | 2004-10-28 | Jallal Messadek | Formulations orales flottantes pour la liberation controlee de la betaine |
| KR101159559B1 (ko) | 2003-08-05 | 2012-06-26 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| BE1016128A6 (fr) * | 2004-07-22 | 2006-03-07 | Messadek Jallal | Combinaisons therapeutiques |
| US7282487B2 (en) * | 2004-10-28 | 2007-10-16 | Idexx Laboratories | Method for treating bacterial infections in horses or pigs with tilmicosin |
| WO2006050581A2 (en) * | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
| BRPI0610249A2 (pt) * | 2005-04-27 | 2010-06-08 | Jallal Messadek | associação ou combinação farmacêutica, composição farmacêutica, processo de co-cristalização e o uso de insulina ou análogo de insulina |
| US20090074882A1 (en) | 2005-12-28 | 2009-03-19 | Novo Nordisk A/S | Insulin compositions and method of making a composition |
| WO2008152106A1 (en) * | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| WO2009065193A1 (en) * | 2007-11-21 | 2009-05-28 | Jallal Messadek | Treatment of aspirin resistance with betaine and/or betaine enriched molasses |
| MX2010009850A (es) | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Analogos de insulina acilados y etabilizados contra proteasas. |
| EP2306986B1 (en) | 2008-06-26 | 2018-03-21 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| EP2344200A2 (en) * | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
| AU2009292643B2 (en) | 2008-09-19 | 2016-02-18 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
| PL2431741T3 (pl) | 2008-10-21 | 2014-01-31 | Baxalta Inc | Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro) |
| CA2738615A1 (en) * | 2008-10-30 | 2010-05-06 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| JP2012519666A (ja) | 2009-03-05 | 2012-08-30 | アセンディス ファーマ エーエス | インターフェロンアルファ担体プロドラッグ |
| WO2011013128A2 (en) | 2009-07-31 | 2011-02-03 | Yeda Research And Development Co. Ltd. | Vectors for delivery of neurotherapeutics to the central nervous system |
| JP5977229B2 (ja) * | 2010-05-05 | 2016-08-24 | プロリンクス リミテッド ライアビリティ カンパニー | 巨大分子共役体からの徐放 |
| JP6049625B2 (ja) | 2010-10-27 | 2016-12-21 | ノヴォ ノルディスク アー／エス | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 |
| EP2490378B1 (en) | 2011-02-18 | 2014-07-09 | NTT DoCoMo, Inc. | Apparatus and method for determining a control unit using feasibility requests and feasibility responses |
| EP2714070B1 (en) | 2011-06-02 | 2024-03-20 | OPKO Biologics Ltd. | Long-acting glp-1/glucagon receptor agonists |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| KR20150002777A (ko) | 2012-04-11 | 2015-01-07 | 노보 노르디스크 에이/에스 | 인슐린 제제 |
| KR102092025B1 (ko) | 2012-06-04 | 2020-03-24 | 옵코 바이오로직스 리미티드 | 페길화된 옥신토모둘린 변이체 |
| US20150111820A1 (en) | 2012-07-09 | 2015-04-23 | Novo Nordisk A/S | Novel use of insulin derivatives |
| WO2014177623A1 (en) | 2013-04-30 | 2014-11-06 | Novo Nordisk A/S | Novel administration regime |
| MA49116A (fr) | 2016-12-16 | 2020-03-25 | Novo Nordisk As | Compositions pharmaceutiques contenant de l'insuline |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| US12441776B2 (en) | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| US20200254065A1 (en) | 2019-02-11 | 2020-08-13 | Opko Biologics Ltd. | Long-acting glp-2 analogs |
| CN114096269B (zh) | 2019-07-12 | 2024-06-11 | 诺和诺德股份有限公司 | 高浓度胰岛素制剂 |
| JP7784993B2 (ja) | 2019-09-30 | 2025-12-12 | 奥金生命科学（宜興）有限公司 | タンパク質－巨大分子コンジュゲート及びその使用方法 |
| CN113773398B (zh) * | 2020-06-10 | 2023-05-23 | 宁波鲲鹏生物科技有限公司 | 一种德谷胰岛素衍生物及其应用 |
| CN117551008B (zh) * | 2023-11-10 | 2025-10-17 | 沈阳药科大学 | 一种去铁胺偶联物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU906340D0 (en) * | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
| GB8717446D0 (en) | 1987-07-23 | 1987-08-26 | Merck Sharp & Dohme | Chemical compounds |
| US6313094B1 (en) * | 1990-12-11 | 2001-11-06 | Japan Energy Corporation | β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors |
| JPH0687887A (ja) * | 1992-08-19 | 1994-03-29 | Upjohn Co:The | ペプチドのエナミン誘導体およびそれをプロドラッグとして含有するペプチド製剤 |
| WO1995000546A1 (en) | 1993-06-25 | 1995-01-05 | Kyowa Hakko Kogyo Co., Ltd. | Endothelin-antagonizing peptide |
| US5880131A (en) * | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| DE4437604A1 (de) * | 1994-10-21 | 1996-04-25 | Basf Ag | Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung |
| JPH10511340A (ja) | 1995-02-09 | 1998-11-04 | ブリガム アンド ウィメンズ ホスピタル | ゲル生成ポリペプチド誘導体 |
| AU5377296A (en) * | 1995-03-30 | 1996-10-16 | Southpac Trust International, Inc. | Self-erecting container which is collapsible to be substanti ally flat |
| US5688992A (en) | 1995-03-31 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof |
| US5846934A (en) * | 1996-02-20 | 1998-12-08 | American Cyanamid Company | Pure somatostatin antagonist and methods of use thereof |
| US6057297A (en) * | 1996-08-06 | 2000-05-02 | Polifarma S.P.A. | Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof |
-
1996
- 1996-08-07 IL IL11902996A patent/IL119029A0/xx unknown
-
1997
- 1997-08-05 EP EP97933828A patent/EP1019089B1/en not_active Expired - Lifetime
- 1997-08-05 AU AU37060/97A patent/AU725468B2/en not_active Ceased
- 1997-08-05 AT AT97933828T patent/ATE308998T1/de active
- 1997-08-05 DE DE69734607T patent/DE69734607T2/de not_active Expired - Lifetime
- 1997-08-05 CA CA002261835A patent/CA2261835C/en not_active Expired - Lifetime
- 1997-08-05 WO PCT/IL1997/000265 patent/WO1998005361A2/en not_active Ceased
- 1997-08-05 ES ES97933828T patent/ES2252787T3/es not_active Expired - Lifetime
- 1997-08-05 IL IL12827497A patent/IL128274A0/xx active IP Right Grant
- 1997-08-05 KR KR1019997000941A patent/KR20000029806A/ko not_active Withdrawn
- 1997-08-05 DK DK97933828T patent/DK1019089T3/da active
- 1997-08-05 BR BR9711045A patent/BR9711045A/pt not_active IP Right Cessation
- 1997-08-05 CN CN97197122A patent/CN1227501A/zh active Pending
- 1997-08-05 NZ NZ333845A patent/NZ333845A/xx unknown
- 1997-08-05 JP JP50777098A patent/JP4416184B2/ja not_active Expired - Lifetime
- 1997-08-05 CZ CZ99369A patent/CZ36999A3/cs unknown
- 1997-08-05 HU HU0000809A patent/HUP0000809A2/hu unknown
- 1997-08-05 US US09/242,026 patent/US6504005B1/en not_active Expired - Lifetime
-
1999
- 1999-01-28 IL IL128274A patent/IL128274A/en not_active IP Right Cessation
- 1999-02-04 NO NO990518A patent/NO990518L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000515542A (ja) | 2000-11-21 |
| ES2252787T3 (es) | 2006-05-16 |
| JP4416184B2 (ja) | 2010-02-17 |
| AU3706097A (en) | 1998-02-25 |
| EP1019089B1 (en) | 2005-11-09 |
| EP1019089A2 (en) | 2000-07-19 |
| CA2261835C (en) | 2008-07-29 |
| CA2261835A1 (en) | 1998-02-12 |
| HUP0000809A2 (hu) | 2000-11-28 |
| BR9711045A (pt) | 1999-08-17 |
| NO990518D0 (no) | 1999-02-04 |
| IL128274A (en) | 2006-08-01 |
| US6504005B1 (en) | 2003-01-07 |
| ATE308998T1 (de) | 2005-11-15 |
| AU725468B2 (en) | 2000-10-12 |
| WO1998005361A2 (en) | 1998-02-12 |
| IL119029A0 (en) | 1996-11-14 |
| NO990518L (no) | 1999-04-06 |
| IL128274A0 (en) | 1999-11-30 |
| DK1019089T3 (da) | 2006-03-13 |
| CN1227501A (zh) | 1999-09-01 |
| DE69734607D1 (de) | 2005-12-15 |
| DE69734607T2 (de) | 2006-08-03 |
| KR20000029806A (ko) | 2000-05-25 |
| CZ36999A3 (cs) | 1999-07-14 |
| WO1998005361A3 (en) | 1998-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ333845A (en) | Long-acting Fmoc-substituted and Fm-substituted pro-drugs | |
| MD420C2 (ro) | Derivaţi ai acidului acrilic | |
| HUP0102793A2 (hu) | Agydaganat kezelésére szolgáló kinazolinok és ezeket tartalmazó gyógyszerkészítmények | |
| ATE297375T1 (de) | Pharmazeutische verbindungen | |
| FI93450B (fi) | Menetelmä terapeuttisesti käyttökelpoisten 10-(1-hydroksietyyli)-11-okso-1-atsatrisyklo/7.2.0.03,8/undek-2-eeni-2-karboksyylihappojohdannaisten valmistamiseksi | |
| DE69825040D1 (de) | Bioabbaubare polymere mit phosphat-endgruppen, zusammensetzungen, gegenstände und verfahren zu ihren herstelling und verwendung | |
| NZ334061A (en) | 2,6,9-trisubstituted purine compounds useful as inhibitors of cyclin dependent kinase 2 | |
| MY100574A (en) | 5-substituted-2-cyclopropyl-6, 8-difluoroquinoline derivatives and processes for preparation thereof | |
| MX9800577A (es) | Derivados de 4,5-diaril oxazol. | |
| AU1227795A (en) | Cosmetic or pharmaceutical compositions consisting of liposomes | |
| EP0632036A3 (en) | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | |
| WO2001026629A3 (en) | Neutral-cationic lipid for nucleic acid and drug delivery | |
| MX9804226A (es) | Derivados novedosos de 2,3,5-trimetil-4-hidroxianilida, su preparacion y su aplicacion de terapeutica. | |
| ATE173249T1 (de) | N,n'-di(aralkyl)-n,n'-di(2- azaaralkyl)alkylendiamin-derivate und ihre verwendung in pharmazeutischen und kosmetischen zusammensetzungen | |
| HUT55032A (en) | Process for producing 19-norsteroids comprising carbon chain substituted in 11beta position by amide or carbamagte group, as well as pharmaceutical compositions comprising such compounds as active ingredient | |
| DE69500511D1 (de) | Phosphatdiester zur Behandlung von proliferativen Erkrankungen der Epidermis | |
| EP0774462A4 (en) | HETEROCYCLIC COMPOUND | |
| DE69006452D1 (de) | Derivate und Analoge von Pyrimidon zur Behandlung von Asthma und bestimmte Hautkrankheiten. | |
| DE60009868D1 (en) | Anti-tumor dihydrochinazolindervate | |
| HUP9900968A2 (hu) | Herbicid hatású szubsztituált-3-aril-pirazol vegyületek, ezeket tartalmazó készítmények, eljárás alkalmazásukra valamint eljárás a vegyületek előállítására | |
| TR199801196T2 (xx) | Biyolojik aktif benzotiyazolon etanaminler. | |
| IE831728L (en) | Sugar derivatives in the treatment of virus infections | |
| EP0299076A4 (en) | 5-hydroxyindole-3-carboxamide compound and medicinal use thereof | |
| NZ514153A (en) | Optically pure camptothecin analogues | |
| GB9612600D0 (en) | Chemical compounds |